A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.

Vakaramoko Diaby a, Reem D. Almutairi b, Ziyan Chen c, Richard K. Moussa d and Abdrahmane Berthe d

a College of Pharmacy, HPNP 3317, University of Florida, Gainesville, FL, USA; b Department of Pharmaceutical Business and Administration Sciences, MCPHS University, Boston, MA, USA; c Théorie Économique, Modélisation et Applications (THEMA), Université de Cergy-Pontoise, France and Ecole Nationale Supérieure de Statistiques et d’Economie Appliquée (ENSEA); d Northwest Territories Government, Yellowknife, Canada

ABSTRACT
Background: Hydroxychloroquine, an antimalarial drug, combined with azithromycin has been considered a potential treatment for COVID-19. However, these drugs may cause electrocardiogram QT prolongation (QTp) and torsade de Pointes (TdP). We examined potential safety signals for these cardiac arrhythmias.

Methods: Using the OpenVigil 2.1 MedDRA platform, we mined data from the U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS) from December 2019 to June 2020. We extracted individual case safety reports based on exposures of seven antimalarial drugs, azithromycin, and combinations. All other drugs in FAERS served as controls. Events of interest included QTp and TdP, with associations between drug exposures and events expressed as adjusted Reporting- Odds-Ratios (aRORs) and confidence intervals. The lower end of aROR 95% confidence interval >1 was used as the statistically significant signal detection threshold.

Results: QTp safety signals were found for hydroxychloroquine [aROR:11.70 (10.40–13.16)], chloroquine [aROR:18.97 (11.30–31.87)], quinine [aROR:16.66 (10.18–27.25)], atovaquone [aROR:6.91 (4.14–11.56)], azithromycin alone [aROR:28.02 (22.87–34.32)] and hydroxychloroquine + azithromycin [aROR:75.23 (51.15–110.66)]. TdP safety signals were found for hydroxychloroquine [aROR: 5.62 (4.94–6.38)], chloroquine [aROR:49.37 (30.63–79.58)], and hydroxychloroquine + azithromycin [aROR:33.09 (21.22–51.61)].

Conclusion: Hydroxychloroquine/chloroquine and/or azithromycin was associated with QTp/TdP safety signals and their use should be monitored carefully.

1. Introduction

In late December 2019, the coronavirus disease 2019 (COVID-19) has started to spread in Wuhan, the capital city of Hubei province, China [1]. The novel coronavirus, SARS-CoV-2 carries a risk for all the population especially the elderly and patients with preexisting conditions. It can lead to severe acute respiratory syndromes, hospitalizations (including intensive care unit admissions), and death in all patients irrespective of age. On 12 March 2020, the World Health Organization (WHO) has declared the COVID-19 outbreak a pandemic [2]. Global data suggest an important epidemiological burden associated with COVID-19. As of 2 October 2020, 34, 495,176 laboratory-confirmed cases had been documented, and a total of 1,025,729 deaths globally [3]. As of October 06, there are a total of 7,436,278 laboratory-confirmed cases and 209,560 deaths in the USA [4].

Measures to slow the spread of COVID-19 include quarantine, social distancing, and isolation [5]. Measures to prevent include the development of vaccines, which is currently a hot research area. Unfortunately, there is currently no vaccine to protect people against COVID-19 [6]. Currently, therapeutic options for patients with COVID-19 mainly focus on experimental drugs (e.g. Aviptadil (RLF-100), tradipitant) as well as the repurposing of existing drugs [7,8]. Among the available therapeutic drugs candidates for repurposing, antimalarial drugs chloroquine (CQ)/hydroxychloroquine (HCQ) have been considered potential ‘miracle cures’ for patients with COVID-19 in light of promising results from clinical trials [9]. CQ/HQ are used to prevent or treat malaria infections caused by plasmodium falciparum and to treat connective tissue diseases such as rheumatoid arthritis and lupus [10].

The results of the study conducted by Gautret et al. suggest a significant reduction in viral load in COVID-19 patients receiving the combination of HCQ and azithromycin [11]. In the face of these results, the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) followed by the US Food and Drug Administration (FDA) issued an emergency use authorization allowing off-label recommendation use of HCQ for COVID-19 as a treatment on 28 March 2020 [12]. These actions from the regulatory bodies in France and the United States have sparked concerns in the clinical and research community over the fact that these drugs have the potential to cause QTp and torsade de Pointes (TdP). Chatre et al. [13] recommended that clinicians be aware of severe and potentially irreversible cardiac toxicities related to the use of
CQ or HCQ in the long-term treatment of connective tissue diseases. These recommendations go a step further by requiring treatments to stop as soon as cardiac manifestations occur. A statement guidelines from the Canadian Heart Rhythm Society mentions that the addition of azithromycin to HCQ may lead to QT prolongation [14]. In the same vein, Das et al [15] conducted a systematic review on the efficacy and safety of the use of HCQ along with azithromycin in COVID-19 patients. They concluded that the use of this treatment combination warrants caution. Finally, there was no evidence of QTp or TdP monitoring in the Gautret et al study [11].

Therefore, there is a critical need to examine safety signals for cardiac arrhythmias (QTp and TdP) from a pharmacovigilance perspective to ensure patient safety, especially in anticipation of high demand and use of CQ/HCQ and/or azithromycin in the war against COVID-19. Besides, several studies have investigated the use of other antimalarial drugs as candidates for repurposing, reemphasizing the importance of conducting pharmacovigilance studies [16,17]. Two pharmacovigilance studies assessed the risk of QTp and TdP following the use of HCO/CQ and or azithromycin using data from the U.S. Food and Drugs Administration Adverse Event Reporting System (FAERS) [18,19]. Although informative, the results of these studies offer limited insights on these safety signals since the data used were obtained in the period pre-COVID-19 (Before December 2019).

The main objective of this study was to determine potential safety signals for QTp and TdP in patients using HCO/CQ and/or azithromycin as treatment candidates for COVID-19 using data from the FAERS from December 2019 to the second quarter of 2020 (peri-COVID-19 period). We also determined potential safety signals for five additional antimalarial drugs alone or in combination with azithromycin.

2. Material and methods

2.1. Study design and data sources

We conducted a disproportionality analysis of the FAERS. FAERS is a publicly available database that contains domestic and foreign information on adverse events and medication error reports submitted to the FDA in the form of ICSRs [20]. ICSRs in the FAERS database provide general administration information including patient characteristics [age, gender (sex)], reporting country, drugs (indications for the drug, concomitant drugs, dosage information and route of administration), events (suspected adverse drug reactions, and medication errors are coded to terms in the Medical Dictionary for Regulatory Activities (MedDRA) terminology, and outcomes [21]. FAERS database follows the international safety reporting guidance issued by the International Conference on Harmonization (ICH E2B) [22].

2.2. Procedures

Using the OpenVigil 2.1 MedDRA platform [23], we mined data from the FAERS from December 2019 to the second quarter of 2020 (551,018 total reports). The OpenVigil 2.1 MedDRA platform allows for the estimation of disproportionality measures used for signal detection.

We used structured query language to extract ICSRs based on exposures of seven antimalarial drugs alone (CQ/HCQ, amodiaquine, quinine, mefloquine, primaquine, atovaquone) and, azithromycin alone, and combinations (exposed). All other drugs in FAERS served as controls (non-exposed to antimalarial drugs/azithromycin).

Two major events (QTp, TdP), suspected to be induced by the treatments (exposure variables) were identified following the MedDRA hierarchy and extracted through OpenVigil 2.1. Example of query logic processes to retrieve frequency counts for events following exposure to HCQ and to create 2 × 2 contingency tables of drug exposure vs event for disproportionality analyses are presented in Appendix 1 and 2 respectively.

Age (categorized as less than 18, 18–64, 65+, Unknown), gender (categorized as male, female, unknown), country (transformed into ‘region’ and categorized as Europe, Asia, Africa, North America, South America, Not specified) were identified from ICSRs. Drugs interacting with antimalarial drugs are likely to increase their plasma concentrations through pharmacokinetic interactions. Drug-drug interactions (DDIs) between antimalarial drugs (CQ/HCQ, amodiaquine, quinine, mefloquine, primaquine, atovaquone) and azithromycin were identified from the summary of the product characteristics (SPC) (Appendix 3).

2.3. Statistical analysis

We conducted a disproportionality analysis to calculate reporting odds ratios (ROs) for signal detection. The estimation of ROs was done for each antimalarial drug, azithromycin, and combinations. We compared the odds of QTp or TdP in ICSRs indicating patients treated with antimalarial drugs and antibiotics (cases) with the odds of QTp or TdP in ICSRs indicating patients treated with all other drugs (non-cases). Additionally, we conducted a robustness analysis by adjusting the calculated ROs for potential confounders including age, gender, and the reporting regions. These suspected confounders were confirmed by the subgroup analyses using the covariates (Data available upon request). The adjusted ROs were calculated using the Mantel-Haenszel approach [24]. Since we aimed to control for categorical variables (or simultaneously for more than one categorical variable), each modality of the categorical variable (or each group formed by the combination of the categorical variables) was treated as a stratum.

Let us consider that we are adjusting the OR for two binary confounding variables denoted Z1 and Z2. The strata are the following: Stratum 1 = (Z1 = 1 and Z2 = 1), Stratum 2 = (Z1 = 1 and Z2 = 0), Stratum 3 = (Z1 = 0 and Z2 = 1) and Stratum 4 = (Z1 = 0 and Z2 = 0). Then, contingency tables are calculated for each stratum as follows:

|        | Y = 1 | Y = 0 |
|--------|-------|-------|
| X = 1  | a1i   | c1i   |
| X = 0  | b1j   | d1j   |

Once these contingency tables are calculated, the Mantel-Haenszel OR (adjusted OR) is calculated as (where l denotes
the number of strata, and \( n_i \) is the number of observation in the stratum):

\[
OR = \frac{\sum_{i=1}^{l} \frac{a_i d_i}{n_i}}{\sum_{i=1}^{l} \frac{c_i d_i}{n_i}}
\]

The standard error is calculated as:

\[
SE = \sqrt{\frac{V}{Q + R}}
\]

Where

\[
Q = \sum_{i=1}^{l} \frac{a_i b_i}{n_i}
\]

\[
R = \sum_{i=1}^{l} \frac{c_i d_i}{n_i}
\]

\[
V = \sum_{i=1}^{l} \frac{(a_i+b_i)(c_i+d_i)(a_i+c_i)(b_i+d_i)}{n_i(n_i-1)}
\]

Thus, the lower (LB) and upper (UB) bounds of the 95% confidence interval are given by:

\[
LB = \exp(\ln(OR) - 1.96 \times SE)
\]

\[
UB = \exp(\ln(OR) + 1.96 \times SE)
\]

The results of the disproportionality analysis were presented using forest plots. All analyses were performed using the statistical software package Stata SE, Release 14 (College Station, TX: StataCorp LP).

3. Results

3.1. Disproportionality analysis: unadjusted analyses

3.1.1. A-electrocardiogram QT prolonged

The crude RORs (cRORs), with their 95% CIs, are presented in Figure 1. When the drugs are used as a single agent, we found safety signals for HCQ [aROR:9.82 (7.79–12.37), p-value: <0.001], CQ [aROR: 18.46 (5.84–58.55), p-value: <0.001], quinine [aROR: 42.95 (20.84–88.53) p-value: <0.001], azithromycin [aROR: 40.10 (28.80–55.83) p-value: <0.001]. When the drugs are used in combination, we only found safety signals for HCQ + azithromycin [aROR: 243.31 (163.40–362.30), p-value: <0.001].

3.1.2. B-Torsade de pointes

When the drugs are used as a single agent, we found safety signals only for CQ [aROR: 46.21 (6.39–334.14). When the drugs are used in combination, we only found safety signals for HCQ + azithromycin [aROR: 71.05 (17.38–290.46), p-value: <0.001].

3.2. Disproportionality analysis: adjusted analyses

3.2.1. A-electrocardiogram QT prolonged

The adjusted RORs (aRORs), with their 95% CIs, are presented in Figure 2. When the drugs are used as a single agent, we found safety signals for HCQ [aROR:11.70 (10.40–13.16), p-value: <0.001], CQ [aROR: 18.97 (11.30–31.87), p-value: <0.001], quinine [aROR: 16.66 (10.18–27.25) p-value: <0.001], azithromycin [aROR: 42.95 (20.84–88.53) p-value: <0.001], etc.
atovaquone [aROR: 6.91 (4.14–11.56), p-value: <0.001], azithromycin alone [aROR: 28.02 (22.87–34.32), p-value: <0.001]. When the drugs are used in combination, we only found safety signals for HCQ + azithromycin [aROR: 75.23 (51.15–110.66), p-value: <0.001].

3.2.2. B-Torsade de pointes
When the drugs are used as a single agent, we found safety signals for HCQ [aROR: 5.62 (4.94–6.38), p-value: <0.001], CQ [aROR: 49.37 (30.63–79.58), p-value: <0.001] (Figure 2). When the drugs are used in combination, we only found safety signals for HCQ + azithromycin [aROR: 33.09 (21.22–51.61), p-value: <0.001].

4. Discussion
In this study, we quantified the risk of QTp and TdP in patients receiving antimalarial drugs (HCQ, amodiaquine, CQ, quinine, mefloquine, primaquine, atovaquone) and azithromycin (individual and combination therapy) from the FAERS December 2019-Second quarter of 2020 through the OpenVigil 2.1 platform. The latter offers an opportunity to generate unbiased pharmacovigilance analyses since it uses cleaned FAERS data [23] (i.e. duplicates and incomplete reports are removed from the original dataset). We found cardiac arrhythmias safety signals associated with several antimalarial drugs, including CQ/HCQ, and/or azithromycin. These results go beyond the already known potential for HCQ and azithromycin to induce cardiac arrhythmias described in the medications’ SPC as these suspected associations are quantified in the current study using a large pharmacovigilance database (FAERS) and labeled as safety signals specifically in the context of COVID-19. For azithromycin, evidence from observational studies in regards to the association between macrolides and cardiovascular events is mixed [16].

Recently, several studies assessed the effectiveness and safety of HCQ with or without azithromycin. From a safety point of view, Sarayani et al. [17] conducted a pharmacovigilance study using data from FAERS (1969–3rd quarter 2019) to examine risks of HCQ with or without azithromycin, including QT segment prolongation, TdP, and death. The authors reported that only azithromycin as a monotherapy was associated with TdP/QT prolongation events, which warrants caution in its use. These results are supported by our findings as it relates to the use of azithromycin alone. As for HCQ/CQ alone or in combination with azithromycin, our results conflict. Potential explanations for these discrepancies may include the differences in data mining approaches used to extract and identify cases and non-cases in the FAERS, the comparator, and denominator used for the measure of association (all other drugs in the FAERS in our study versus amoxicillin in Sarayani et al) and the time horizon covered by the data.
(1963- December 2019, the period before COVID-19). A similar study by Singh et al. aimed at determining and characterizing HCQ-associated cardiovascular adverse events (CV-AEs) [18]. Our results are in agreement with the findings of the study by Singh et al. as it relates to HCQ. Though, the magnitude of our findings is greater given that the aROR for HCQ is significantly higher than the one reported by Singh et al. This may be due to our study using FAERS data during the COVID-19 period (December 2019–2nd quarter of 2020) while Singh et al. used FAERS data for the period from 29 May 1998, to 31 December 2019. The scope of the current study is broader as it examined seven antimalarial drugs alone or in combination with azithromycin, with ROR adjusted for potential confounders.

Rosenberg et al. [25] conducted a multicentre retrospective cohort study of adverse effects of HCQ among patients with COVID-19. Cardiac arrest was more frequent in patients who received HCQ with azithromycin, compared with patients who received neither drug, even after adjustment. Mercuro et al. [26] conducted a study to characterize the risk and degree of QT prolongation in patients with COVID-19 in association with their use of HCQ with or without concomitant azithromycin. They found that patients who were hospitalized and received HCQ for COVID-19 frequently experienced QTc prolongation and ADEs, including a case of torsades de pointes with the administration of HCQ and azithromycin. Chorin et al. [27] conducted a retrospective study of 251 patients diagnosed with COVID-19 and treated with HCQ + azithromycin to determine the risk for cardiac arrhythmias and death. The authors concluded that HCQ + azithromycin significantly prolongs the QTc interval in patients with COVID-19. These results are consistent with our findings.

With the increasing utilization of spontaneous reporting systems for post-marketing surveillance and pharmacovigilance, several well-recognized limitations of the database should be noted. As the reporting of adverse events is passive, it is subject to inherent limitations that may introduce selection bias to the analysis using the database [28]. The limitations are underreporting, overreporting, and data quality. Underreporting is common due to several reasons. First, it is hard to determine whether a drug is the root cause of an adverse event. Second, physicians only report serious or unexpected adverse events. Third, physicians may be reluctant to report an adverse event due to different reasons such as lack of time. Overreporting is less common than under-reporting. It is believed that the reports are skewed to more extensively used drugs and more serious adverse events. The data quality in spontaneous reporting is not perfect. First, some mistakes could be made due to the manual reporting process. Second, some data elements may be missing or incomplete including dosage, clinical indications, and drug-drug interactions. Third, reports could be duplicated due to multiple reporting sources. Fourth, reports do not follow a strict format. Unlike clinical trials, the spontaneous reporting system that collects information on adverse events relies on passive and opportunistic reporting. This causes a long-standing issue of missing denominators, which indicates the accurate number of patients taking the drug. Thus, it is hard to establish a causal relationship between a drug and an adverse event. Notwithstanding these limitations, this study is the first one to quantify the association between seven antimalarial drugs and/or azithromycin and cardiovascular adverse events. The case/non-case method used is known to be able to detect relatively rare signals for adverse drug reactions (ADRs) such as QTp and TdP [29,30].

5. Conclusion

In the face of COVID-19 and the quest for effective and safe treatments, we recommend that a careful risk-benefit assessment be performed in patients with a previous history of cardiac disorders (and especially cardiac arrhythmia) requiring CQ, HCQ, quinine, atovaquone alone or in combination with azithromycin. In these at-risk patients, periodic and close cardiac monitoring with clinical evaluation and electrocardiograms are warranted.

Author contributions

Conceptualization: Vakaramoko Diaby, Reem D. Almutairi, Ziyan Chen, Richard K. Moussa; Writing – original draft preparation: Vakaramoko Diaby, Reem D. Almutairi, Ziyan Chen, Richard K. Moussa, Abdrahmane Berthe; Writing – review and editing: Vakaramoko Diaby, Reem D. Almutairi, Ziyan Chen, Richard K. Moussa, Abdrahmane Berthe; Supervision: Vakaramoko Diaby. All authors read and approved the final manuscript.

Acknowledgments

The data from the FAERS come from a variety of sources. The likelihood of a causal relationship is not the same in all reports. The information does not represent the opinion of the Food and Drug Administration.

Data availability

The data that support the findings of this study can be accessed upon request to the Food and Drug Administration or through the OpenVigil platform [http://openvigil.sourceforge.net].

Research involving human participants and/or animals: Not applicable

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Funding

This study was not funded.

Informed consent

Not applicable

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewers disclosure

Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.
References

Papers of special note have been highlighted as either of interest (-) or of considerable interest (••) to readers.

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
2. World Health Organization. Europe, WHO announces COVID-19 outbreak a pandemic. [updated 2020 Mar 12; cited 2020 Mar 17]. Available from: http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic
3. World Health Organization. Coronavirus disease 2019 (COVID-19). Situation Report. [Updated 2020 Oct 2; cited 2020 Oct 6]. Available from: https://www.who.int/publications/m/item/weekly-update-on-covid-19—2—october-2020
4. Center for Disease Control and Prevention (CDC). [Updated 2020 Oct 6; cited 2020 Oct 6]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
5. Center for Disease Control and Prevention (CDC). Coronavirus disease 2019 (COVID-19), prevent getting sick. [Updated 2020 Apr 11; cited 2020 Apr 11]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/social-distancing.html
6. USFDA. Coronavirus Disease 2019 (COVID-19). [Updated 2020 Apr 4; cited 2020 Apr 11]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19
7. Nitulescu GM, Paunescu H, Moschos SA, et al. Comprehensive analysis of drugs to treat SARS-CoV-2 infection: mechanistic insights into current COVID-19 therapies (Review). Int J Mol Med. 2020;46:467–488.

• Article of interest
8. Alexander SP, Armstrong JF, Davenport AP, et al. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR review 29. Br J Pharmacol. 2020 May 1;177:4942–4966. Epub ahead of print. PMID: 32358833; PMCID: PMC7267163.

• Article of interest
9. Schlagenhauf P, Grobusch MP, Maier JD, et al. Repurposing anti-malarials and other drugs for COVID-19. Travel Med Infect Dis. 2020 Mar;34:101658.
10. USFDA. Drugs@FDA: FDA-approved drugs. [Updated 2020 Mar 19; cited 2020 Apr 11]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&AppNo=009768
11. Gautret P, Lagier J, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.

• Article of considerable interest
12. USFDA. Coronavirus (COVID-19) update: FDA continues to facilitate development of treatments. [Updated 2020 Mar 19; cited 2020 Apr 11]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-facilitate-development-treatments
13. Chatte C, Roubille F, Vernet H, et al. Cardiac complications associated to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41:919–931.

• Article of considerable interest
14. Sapp JL, Alqarawi W, MacIntyre CJ, et al. Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian heart rhythm society. Can J Cardiol. 2020;36:948–951.

• Article of interest
15. Das S, Bhownick M, Tiwari S, et al. An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease 19 (COVID 19). Clin Drug Investig. 2020;40:591–601.

• Article of interest
16. Sachdeva C, Wadhwa A, Kumari A, et al. In silico potential of approved antimalarial drugs for repurposing against COVID-19. OMICS. 2020;24:568–580. https://www.liebertpub.com/doi/10.1089/OML.2020.0071.

• Article of interest
17. Gendrot M, Andreani J, Buxberger M, et al. Antimalarial drugs inhibit the replication of SARS-CoV-2: an in vitro evaluation. Travel Med Infect Dis. 2020;37:101873. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477610/.

• Article of interest
18. Sarayani A, Cicalli B, Henriksen C, et al. Safety signals for QT prolongation or torsades de pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Soc Adm Pharm. Published online 2020 Apr 19;S1551-7411(20)30391-0. doi:10.1016/j.sapharm.2020.04.016. Online ahead of print.

• Article of interest
19. Singh AP, Tousif S, Umbarkar P, et al. A pharmacovigilance study of hydroxychloroquine cardiac safety profile: potential implication in COVID-19 mitigation. J Clin Med. 2020;9(6):1867.

• Article of interest
20. Sonawane KB, Cheng N, Hansen RA. Serious adverse drug events reported to the FDA: analysis of the FDA adverse event reporting system 2006–2014 database. JMCP. 2018;24:662–690.

21. USFDA. Questions, and answers on FDA’s adverse event reporting system (FAERS). [Updated 2020 Apr 4; cited 2020 Apr 17]. Available from: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers

22. USFDA. Coronavirus disease 2019 (COVID-19). [Updated 2020 Apr 4; cited 2020 Apr 11]. Available from: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers

23. USFDA. FDA adverse event reporting system (FAERS) electronic submissions. [Updated 2020 Mar 3; cited 2020 Apr 17]. Available from: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers-electronic-submission

24. Tripepi G, Jager KJ, Dekker F, et al. Stratification for confounding – part 1: the Mantel-Haenszel formula. Nephron Clin Pract. 2010;116:c317–c321.

• Article of interest
25. Rosenberg E, Dufort E, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in NewYork state. JAMA. Published online 2020 May 11;323:2493.

• Article of interest
26. Mercuro N, Yen C, Shim D, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 May 1:e201834.

• Article of interest
27. Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/ azithromycin. Heart Rhythm. 2020 Sep;17(9):1425–1433. Epub 2020 May 12. PMID: 32407884; PMCID: PMC7214283.

28. Palleria C, Leporini C, Chimiri S, et al. Limitations and obstacles of the spontaneous adverse drug reactions reporting: two “challenge” case reports. JPP. 2013;4:566.

29. Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905–908.

30. Faillie JL, Oriana HY, Yin H, et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176:1474–1481.
Appendix 1. Example: Query processing logic to estimate the frequency of adverse drug reactions for Hydroxychloroquine

```sql
SELECT pt AS event,
       COUNT(pt) AS Count_ISR,
       COUNT(DISTINCT Case_id) AS Count_independent_cases
FROM public.rep_event,
     public.report
WHERE report.isr = rep_event.isr
  AND rep_event.isr = ANY(
    [
      SELECT report.isr
        FROM public.report
    ]
  )
ORDER BY Count_ISR DESC
```

Appendix 2. Example: Query processing logic used to generate a 2 × 2 contingency table for the disproportionality analysis for hydroxychloroquine and QT prolongation

```sql
SELECT COUNT(DISTINCT isr) AS count
FROM public.report
WHERE isr = ANY(
  [  
    SELECT report.isr
      FROM public.report
    ]
  )
  AND drugusage.isr = report.isr
)
  AND lower(product.brandname) = lower('hydroxychloroquine')
)
  AND lower(product.drugname) = lower('hydroxychloroquine')
)
ORDER BY COUNT_ISR DESC
```

```sql
UNION

[
  SELECT report.isr
    FROM public.report
WHERE
  [
    SELECT *
      FROM public.drugusage
WHERE
    [
      drugusage.brandname IS NULL
      AND EXISTS(
        SELECT *
          FROM d_appl
        WHERE
          d_appl.drug_seq = drugusage.drug_seq
        AND lower(d_appl.drugname) = lower('hydroxychloroquine')
      ]
    )
    AND drugusage.isr = report.isr
  ]
]
)
)
WHERE
  [
    SELECT *
      FROM public.drugusage
WHERE
    [
      drugusage.brandname IS NOT NULL
      AND EXISTS(
        SELECT *
          FROM product
        WHERE
          lower(product.brandname) = lower('hydroxychloroquine')
        AND lower(product.drugname) = lower('hydroxychloroquine')
      )
    )
    AND drugusage.isr = report.isr
  ]
]
)
UNION
(
    SELECT
        report.isr
    FROM
        public.report
    WHERE
        (EXISTS(
            SELECT *
            FROM
                public.drugusage
            WHERE
                drugusage.brandname IS NOT NULL
                AND EXISTS(
                    SELECT *
                    FROM
                        product
                    WHERE
                        lower(product.brandname) = lower(drugusage.brandname)
                        AND lower(product.drugname) = lower('hydroxychloroquine')
                )
        )
        AND drugusage.isr = report.isr
)
)
INTERSECT(SELECT
    report.isr
FROM
    public.report
WHERE
    (EXISTS(SELECT *
        FROM
            public.rep_event
        WHERE
            report.isr = rep_event.isr
            AND rep_event.pt = 'electrocardiogram qt prolonged')
)
)
)

Query Sum Drug:
SELECT
    COUNT(DISTINCT isr) AS count
FROM
    public.report
WHERE
    isr = ANY(
        (SELECT
            report.isr
            FROM
                public.report
            WHERE
                (EXISTS(
                    SELECT *
                    FROM
                        public.drugusage
                    WHERE
                        drugusage.brandname IS NULL
                        AND EXISTS(
                            SELECT *
                            FROM
                                d_appl
                        WHERE
                            d_appl.drug_seq = drugusage.drug_seq
                            AND lower(d_appl.drugname) = lower('hydroxychloroquine')
                    )
                )
                AND drugusage.isr = report.isr
            )
        )
    )
)

Query Sum Adverse Event:
SELECT
    COUNT(DISTINCT isr) AS count
FROM
    public.report
WHERE
    isr = ANY(
        (SELECT
            report.isr
            FROM
                public.report
            WHERE
                (EXISTS(
                    SELECT *
                    FROM
                        public.rep_event
                    WHERE
                        report.isr = rep_event.isr
                        AND rep_event.pt = 'electrocardiogram qt prolonged'
                )
        )
    )
)

Query Sum Drug/Adverse Event:
SELECT
    COUNT(DISTINCT isr) AS count
FROM
    public.report
WHERE
    1=1
### Appendix 3.

**Table 1. Common chloroquine drug-drug interactions.**

| Drug Interactions                                      | Effect                                                                 | Recommendation                                                                                     |
|--------------------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| Digoxin                                                | Concomitant use of hydroxychloroquine and digoxin therapy may result in increased serum digoxin levels:   | Serum digoxin levels should be closely monitored in patients receiving combined therapy             |
| Insulin or antidiabetic drugs                          | As hydroxychloroquine may enhance the effects of a hypoglycemic treatment | A decrease in doses of insulin or antidiabetic drugs may be required                               |
| Drugs that prolong QT interval and other arrhythmogenic drugs | Hydroxychloroquine prolongs the QT interval                           | should not be administered with other drugs that have the potential to induce cardiac arrhythmias. Also, there may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine is used concomitantly with other arrhythmogenic drugs. |
| Mefloquine and other drugs that are known to lower the convulsive threshold | Hydroxychloroquine can lower the convulsive threshold. Co-administration of hydroxychloroquine with other antimalarials known to lower the convulsion threshold (e.g., mefloquine) may increase the risk of convulsions. | -                                                                                                    |
| Antiepileptics                                         | The activity of antiepileptic drugs might be impaired if co-administered with hydroxychloroquine.         | -                                                                                                    |
| Methotrexate                                           | The combined use of methotrexate with hydroxychloroquine has not been studied and may increase the incidence of adverse effects. | -                                                                                                    |
| Cyclosporin                                            | An increased plasma cyclosporine level was reported when cyclosporine and hydroxychloroquine were co-administered | -                                                                                                    |
| Praziquantel                                           | Chloroquine has been reported to reduce the bioavailability of praziquantel.                               | -                                                                                                    |
| Antacids and kaolin                                    | Antacids and kaolin can reduce the absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. | Concomitant use of cimetidine should be avoided.                                                     |
| Cimetidine                                             | Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.                          | Concomitant use of cimetidine should be avoided.                                                     |
| Ampicillin                                             | Chloroquine significantly reduced the bioavailability of ampicillin.                                        | -                                                                                                    |

Sources: US Food and Drug Administration (FDA) website